ClinicalTrials.gg
CompletedNCT02072525Updated Nov 27, 2017

A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays

A Phase 4 interventional study of Menveo® and Boostrix® in Meningococcal, sponsored by GlaxoSmithKline. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-27.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
359
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing boostrix in Whooping Cough — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Whooping Cough.

Enrollment
9th of 12
359 · median 548
Started
2014
the only one that year
Phase 4
5 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
6 of 12
GlaxoSmithKline

Among the 12 studies testing boostrix in Whooping Cough, this one is the 9th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 4, and was the 6th registered.

Whooping Cough

290 studies on the registry are indexed under Whooping Cough; 23 are open to participants now.

Browse Whooping Cough studies →

Open to participants now

2 of the 12 studies testing boostrix in Whooping Cough are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About boostrix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 14 Whooping Cough studies recruiting now, 2 (14%) set no upper age limit and 11 (79%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing boostrix in Whooping Cough, or all of them as a file.
02

Study summary

The purpose of this study is to collect serum samples for use as quality control samples in GSK assays. The serum samples need to include samples with low, medium and high antibody titers/concentrations, which cover the assay range.

Read the detailed description

The purpose of this protocol is to source human serum from plasma from healthy adults for use as control samples in the assays supporting the clinical development of GSK Biologicals' vaccines for the prevention of invasive infections caused by Neisseria meningitidis, Streptococcus pneumoniae, Corynebacterium diphtheriae, Clostridium tetani and Bordetella pertussis. At the final visit, a small volume of whole blood will be obtained in addition to plasma, to allow for head to head comparison of serum obtained from whole blood (off-clot serum) and from plasma (serum derived from re-calcified plasma). In addition, sera generated in this clinical trial could potentially be used as control samples for other vaccine programs to help assure the quality of the analytical methods.

Subjects 18 through 49 years of age (have not yet achieved 50th birthday) will be randomized to receive Menveo + Boostrix and subjects 50 to 55 years of age will be randomized to receive either Pneumovax 23 or Prevnar 13 and will serve as donors of human serum in this study.

03

Conditions studied

  • Meningococcal

Keywords

  • Pertussis
  • Healthy adults
  • Tetanus
  • Human serum samples
  • Streptococcus
  • Diphtheria
  • Plasma
  • Meningococcus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female between, and including, 18 and 55 years of age at the time of the first vaccination.
  • Written obtained from the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study, with no medical conditions that in the opinion of the investigator prevents the subject from participating in the study.
  • Subjects must weigh at least 110 pounds (50 kg).
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for at least 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception for the entire duration of the subject's participation in the trial.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) within 30 days preceding the dose of study vaccine, or planned use during the study period.
  • Subjects seropositive for surface antigen (HBsAg), antibody to virus (anti-HCV) or .
  • Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs within six months prior to the vaccine dose. Inhaled and topical are allowed.
  • Administration of long-acting immune-modifying drugs at any time during the study period.
  • Any antibiotic taken during the period from 14 days before the collection of plasma up to the day of collection of plasma.
  • Any medication based on methyl phenidate HCL such as Metadate® or Concerta® or other CNS stimulants used to treat attention-deficit disorder or attention-deficit hyperactivity disorder taken during the period of 14 days before the collection of plasma up to the day of collection of plasma.
  • Subjects who donated >500 mLs of blood within 60 days prior to any plasma collection visits (plasmapheresis).
  • Subjects who lost >200 mL of red blood cells during a single apheresis procedure or lost red blood cells on more than one occasion during apheresis within the previous 60 days.
  • Ongoing anemia as indicated by either (i) values, (ii) serum ferritin, or (iii) hematocrit values below the lower limit of the laboratory-specified reference range. If the laboratory results demonstrate an anemia, no further protocol procedures will be performed, and the subject will be referred for appropriate medical management. The subject may participate in this study following therapy and evidence that the anemia has been resolved.
  • Bleeding disorder and/or a clinical laboratory count value below the lower limit of the laboratory-specified reference range.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and 30 days after the dose of vaccine, with the exception of licensed inactivated influenza vaccine.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Family history of congenital or hereditary immunodeficiency.
  • History of any reaction or likely to be exacerbated by any component of the vaccine(s).
  • Hypersensitivity to latex.
  • Serious chronic illness.
  • Acute disease and/or fever at the time of vaccination (Day 0).

    • Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C /100.4°F on rectal route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • Acute or chronic, pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
  • History of chronic alcohol consumption and/or drug abuse.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary) based on medical history and history directed physical examination (no laboratory testing at the screening visit is required).

Additional exclusion criteria for subjects 18-49 years of age

  • Previous vaccination against diphtheria and/or tetanus within the past 5 years and/or Neisseria meningitidis since birth.
  • Progressive neurological disorders, including uncontrolled epilepsy or progressive encephalopathy.
  • Subjects who have experienced an encephalopathy of unknown etiology, occurring within 7 days following previous vaccination with a pertussis containing vaccine.
  • Subjects who have experienced transient thrombocytopenia or neurological complications following an earlier immunization against diphtheria and/or tetanus.
  • If any of the following events had occurred in temporal relation to previous administration of whole-cell DTP or acellular DTP vaccine:

    • Temperature of ≥ 40.0°C within 48 hours of vaccination, not due to another identifiable cause.
    • Collapse or shock like state (hypotonic hyporesponsive episode) within 48 hours of vaccination.
    • Persistent, inconsolable crying lasting ≥ 3 hours, occurring within 48 hours of vaccination.
    • Convulsions with or without fever, occurring within 3 days of vaccination.

Additional exclusions criterion for subjects 50-55 years of age

  • Previous vaccination against Streptococcus pneumoniae.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
359 participants (actual)

Study arms

  • Experimental
    Mtdap1 Group

    Subjects will receive concomitant doses of Menveo and Boostrix.

    Biological: Menveo® · Biological: Boostrix®

  • Experimental
    Mtdap2 Group

    Subjects will receive concomitant doses of Menveo and Boostrix.

    Biological: Menveo® · Biological: Boostrix®

  • Experimental
    Mtdap3 Group

    Subjects will receive concomitant doses of Menveo and Boostrix.

    Biological: Menveo® · Biological: Boostrix®

  • Experimental
    Pneum1 Group

    Subjects will receive a dose of Pneumovax 23.

    Biological: Pneumovax 23®

  • Experimental
    Pneum2 Group

    Subjects will receive a dose of Pneumovax 23.

    Biological: Pneumovax 23®

  • Experimental
    Pneum 3 Group

    Subjects will receive a dose of Pneumovax 23.

    Biological: Pneumovax 23®

  • Experimental
    Prev1 Group

    Subjects will receive a dose of Prevnar 13.

    Biological: Prevnar 13®

  • Experimental
    Prev2 Group

    Subjects will receive a dose of Prevnar 13.

    Biological: Prevnar 13®

  • Experimental
    Prev3 Group

    Subjects will receive a dose of Prevnar 13.

    Biological: Prevnar 13®

Interventions

  • BiologicalMenveo®

    One dose administered intramuscularly (IM) in the upper left deltoid of the arm.

  • BiologicalBoostrix®

    One dose administered intramuscularly (IM) in the upper right deltoid of the arm.

  • BiologicalPneumovax 23®

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.

  • BiologicalPrevnar 13®

    One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.

06

What researchers measure

Primary outcomes

  1. Collection of human plasma for conversion into serum.

    Collection of human plasma for conversion into serum for use as control samples in GSK Biologicals' assays in support of Neisseria meningitidis, Streptococcus pneumoniae, Corynebacterium diphtheriae, Clostridium tetani and Bordetella pertussis vaccine development programs.

    Time frame: At Visit 2 (Day 0).

  2. Collection of human plasma for conversion into serum.

    Collection of human plasma for conversion into serum for use as control samples in GSK Biologicals' assays in support of Neisseria meningitidis, Streptococcus pneumoniae, Corynebacterium diphtheriae, Clostridium tetani and Bordetella pertussis vaccine development programs.

    Time frame: At 10 days post-vaccination.

  3. Collection of human plasma for conversion into serum.

    Collection of human plasma for conversion into serum for use as control samples in GSK Biologicals' assays in support of Neisseria meningitidis, Streptococcus pneumoniae, Corynebacterium diphtheriae, Clostridium tetani and Bordetella pertussis vaccine development programs.

    Time frame: At 30 days post-vaccination.

  4. Collection of human plasma for conversion into serum.

    Collection of human plasma for conversion into serum for use as control samples in GSK Biologicals' assays in support of Neisseria meningitidis, Streptococcus pneumoniae, Corynebacterium diphtheriae, Clostridium tetani and Bordetella pertussis vaccine development programs.

    Time frame: At 60 days post-vaccination.

  5. Collection of human plasma for conversion into serum.

    Collection of human plasma for conversion into serum for use as control samples in GSK Biologicals' assays in support of Neisseria meningitidis, Streptococcus pneumoniae, Corynebacterium diphtheriae, Clostridium tetani and Bordetella pertussis vaccine development programs.

    Time frame: At 120 days post-vaccination

Secondary outcomes

  1. Occurrence of serious adverse events related to vaccination and to lack of vaccine efficacy throughout the study.

    Time frame: Throughout the study (Day 0 to Day 30 - Day 180).

07

Study locations

1 site
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 2G2, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Jun 2015, 14 months.

Of 22 phase 4 interventional studies under Whooping Cough, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2014
First posted
Feb 26, 2014
StartActual
Apr 1, 2014
Primary completionActual
Jun 2, 2015
CompletionActual
Jun 2, 2015
Last update
Nov 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02072525
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 26, 2014
Start date
Apr 1, 2014
Primary completion
Jun 2, 2015
Completion
Jun 2, 2015
Last update
Nov 27, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Boostrix · 23-valent pneumococcal capsular polysaccharide vaccine · 13-valent pneumococcal vaccine

Start the discussion